Last reviewed · How we verify

Neostigmine with glycopyrrolate

The Cleveland Clinic · FDA-approved active Small molecule

Neostigmine with glycopyrrolate is a Acetylcholinesterase inhibitor with anticholinergic agent Small molecule drug developed by The Cleveland Clinic. It is currently FDA-approved for Reversal of neuromuscular blockade after anesthesia, Myasthenia gravis.

Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects.

Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects. Used for Reversal of neuromuscular blockade after anesthesia, Myasthenia gravis.

At a glance

Generic nameNeostigmine with glycopyrrolate
SponsorThe Cleveland Clinic
Drug classAcetylcholinesterase inhibitor with anticholinergic agent
TargetAcetylcholinesterase; muscarinic acetylcholine receptors
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Neostigmine is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at the neuromuscular junction and in the central nervous system. Glycopyrrolate is an anticholinergic agent added to this combination to prevent excessive muscarinic stimulation (salivation, bronchospasm, bradycardia) that would otherwise result from neostigmine monotherapy. Together, they enhance nicotinic effects while minimizing unwanted muscarinic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Neostigmine with glycopyrrolate

What is Neostigmine with glycopyrrolate?

Neostigmine with glycopyrrolate is a Acetylcholinesterase inhibitor with anticholinergic agent drug developed by The Cleveland Clinic, indicated for Reversal of neuromuscular blockade after anesthesia, Myasthenia gravis.

How does Neostigmine with glycopyrrolate work?

Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects.

What is Neostigmine with glycopyrrolate used for?

Neostigmine with glycopyrrolate is indicated for Reversal of neuromuscular blockade after anesthesia, Myasthenia gravis.

Who makes Neostigmine with glycopyrrolate?

Neostigmine with glycopyrrolate is developed and marketed by The Cleveland Clinic (see full The Cleveland Clinic pipeline at /company/the-cleveland-clinic).

What drug class is Neostigmine with glycopyrrolate in?

Neostigmine with glycopyrrolate belongs to the Acetylcholinesterase inhibitor with anticholinergic agent class. See all Acetylcholinesterase inhibitor with anticholinergic agent drugs at /class/acetylcholinesterase-inhibitor-with-anticholinergic-agent.

What development phase is Neostigmine with glycopyrrolate in?

Neostigmine with glycopyrrolate is FDA-approved (marketed).

What are the side effects of Neostigmine with glycopyrrolate?

Common side effects of Neostigmine with glycopyrrolate include Bradycardia, Muscle fasciculations, Increased salivation (despite glycopyrrolate), Bronchospasm, Nausea.

What does Neostigmine with glycopyrrolate target?

Neostigmine with glycopyrrolate targets Acetylcholinesterase; muscarinic acetylcholine receptors and is a Acetylcholinesterase inhibitor with anticholinergic agent.

Related